Please find all related articles below.
14 October 2014, Brussels - . The European Commission’s High Level Group on Administrative Burdens (1), chaired by Dr Edmund Stoiber, has drawn severe criticism from 4 of a total of 15 Members (2) for its final report (3) pushing an outdated, deregulatory agenda.
Almost one third of ‘Stoiber group’ members oppose biased final report
The views of members representing trade unions, environmental groups, consumer organisations and health groups are presented in a (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
8th October 2014, Brussels - With regard to the planned transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (#Pharma4Health campaign), we would like to inform you that the Conference of the Presidents of the European Parliament (composed of the President of the European Parliament, Martin Schulz and the leaders of the political groups) will meet tomorrow on 9th October (Thursday).
Dear EPHA Members,
We would like to (...)
1 October 2014, Brussels - By European Parliament standards, Commissioner-designate Vytenis Andriukaitis’ performance could be judged to be “satisfactory”. He showed his commitment to protect European citizens’ health and well-being, and improve underlying determinants of health and physical environment. Now we will really have to see how he intends to turn words into concrete action. He was very outspoken on the issues of prevention, promotion and protection of (...)
Vytenis Andriukaitis - European Commissioner-designate for Health and Food Safety
Elżbieta Bieńkowska » European Commissioner-designate for Internal Market, Industry, Entrepreneurship and SMEs
Cecilia Malmström » European Commissioner-designate for Trade
Pierre Moscovici » Commissioner-designate for Economic and Financial Affairs, Taxation and Customs
Phil Hogan » European Commissioner-designate for Agriculture
Marianne Thyssen » European Commissioner-designate for (...)
From 1 November 2014, Cecilia Malmström will take office as the new Commissioner for Trade, under the Juncker Commission. The appointment of Swedish native Ms. Malmstrom implies that the President-elect of the European Commission, Jean-Claude Juncker, would like to further promote discussion with the U.S. on the much debated Transatlantic Trade and Investment Partnership (TTIP).
By Leonardo Palumbo, EPHA Policy Coordinator for EU Affairs and Arthur Matthews, Policy Assistant
For the crucial Commissioner portfolio comprising Employment, Social Affairs, Skills and Labour Mobility, President-elect Jean-Claude Juncker has nominated Marianne Thyssen from Belgium. As part of her designated responsibilities, Ms Thyssen’s responsibilities will include issues related to the free movement of workers and migration, skills development and promotion of lifelong learning, to ensure that European labour markets are able to deliver jobs and growth.
By Sascha Marschang, (...)
Frans Timmermans has been officially designated to be one of the six Vice-Presidents and the First Vice-President in charge of Better Regulation, Inter-Institutional Relations, the Rule of Law and the Charter of Fundamental Rights – a newly installed Directorate General.
By Dorota Sienkiewicz, EPHA Health Equity and Policy Coherence Coordinator
Putting in place this brand new DG reflects the EU’s new strategy to focus on areas where it can make a difference (in its own (...)
After months of inaction and neglect from the international community, the Ebola epidemic in west Africa has now spiralled utterly out of control. Today, the virus is a threat not only to the countries where the outbreak has overwhelmed the capacity of national health systems, but also to the entire world.
We urge our governments to mobilise all possible resources to assist west Africa in controlling this horrific epidemic. Based on our (...)
A study in Germany, France and the Netherlands highlights an alarming trend: the majority of medicines granted marketing authorisation has no added therapeutic value (ATV) compared to medicines already on the market. In some cases the new medicine even did more harm than good. These are the results of a research conducted by Wemos and EPHA. The figures are based on evaluations of several international drug bulletins.
1st October 2014, Brussels - The French drug bulletin La Revue Prescrire (...)